Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02807181 · ClinicalTrials.gov registry record · Phase 2
SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
A Phase 2 study, sponsored by Sirtex Medical.
- Terminated
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT02807181: Clinical Trial Phase 2 study, sponsored by Sirtex Medical.
NCT02807181 is a Phase 2 study that was terminated before completion, run by Sirtex Medical. The registered enrollment target is 89 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02807181, a Phase 2 study, was terminated before completion, sponsored by Sirtex Medical.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
The study planned to evaluate the benefit of applying Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin microspheres prior to receiving systemic chemotherapy treatment (cisplatin-gemcitabine, or CIS-GEM) in patients with unresectable intrahepatic cholangiocarcinoma. Half of the patients were randomized to CIS-GEM chemotherapy plus SIRT, and half of the patients were randomized to CIS-GEM alone.
Primary Outcome
Survival at 18 months is defined as the proportion of patients still alive 18 months from the date of randomization. The outcome was analyzed but the clinical database is not deemed to be reliable.
Interventions
- DRUG Cisplatin-gemcitabine
- DEVICE Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2017-02-14 |
| Est. Completion | 2021-04-29 |
| Phase | Phase 2 |
Why NCT02807181 stopped before completion
NCT02807181 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 2 interventions - of which Cisplatin-gemcitabine is the first listed.
NCT02807181 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02807181 about?
NCT02807181 is a clinical study titled "SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma". The study planned to evaluate the benefit of applying Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin microspheres prior to receiving systemic chemotherapy treatment (cisplatin-gemcitabine, or CIS-GEM) in patients with unresectable intrahepatic cholangiocarcinoma. Half of th...
What is the current status of trial NCT02807181?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2017-02-14. Estimated completion is 2021-04-29.
What interventions are being tested in trial NCT02807181?
The interventions under investigation include: Cisplatin-gemcitabine (DRUG), Radiation: SIRT + chemotherapy (cisplatin-gemcitabine) (DEVICE).
Who is sponsoring clinical trial NCT02807181?
This trial is sponsored by Sirtex Medical, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02807181's enrollment target sits among peer trials
89 802nd of 2000 higher than 1,198 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI